Search Result

Results for "

glucose concentration

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (2) SGLT (2) Acetolactate Synthase (ALS) (1) Autophagy (1) Biochemical Assay Reagents (1) Endogenous Metabolite (6) Free Fatty Acid Receptor (1) Fungal (1) GCGR (1) Lipoxygenase (1) Photosystem II (1) PPAR (1) Somatostatin Receptor (1) TNF Receptor (1) Topoisomerase (1)
By Research Areas:	Cancer (5) Endocrinology (2) Inflammation/Immunology (1) Metabolic Disease (12)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109500

Masoprocol meso-Nordihydroguaiaretic acid; meso-NDGA	Lipoxygenase	Metabolic Disease Cancer
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose* reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose* reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-158583

13-POHSA	Endogenous Metabolite	Metabolic Disease
13-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

HY-158584

13-OAHSA 9Z-Octadecenoic acid, 12-carboxy-1-pentyldodecyl ester	Endogenous Metabolite	Metabolic Disease
13-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-OAHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

HY-158639

12-POHSA	Endogenous Metabolite	Metabolic Disease
12-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 12-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

HY-148247

BI-2081	Free Fatty Acid Receptor	Metabolic Disease
BI-2081 is a GPR40 (FFAR1) partial agonist (EC₅₀: 4 nM). BI-2081 induces glucose depending insulin secretion and reduces the plasma glucose concentration. BI-2081 can be used in the research of metabolic diseases, in particular diabetes type 2 .

HY-158650

10-OAHSA	Endogenous Metabolite TNF Receptor	Inflammation/Immunology Endocrinology
10-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 10-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration. 10-OAHSA reduces LPS (HY-D1056)-induced Tnf-α secretion in bone marrow-derived dendritic cells (BMDCs) .

HY-118113

BVT-116429	Others	Others
BVT-116429 is an 11βHSD1 inhibitor with the activity of increasing adiponectin concentration and improving glucose homeostasis in diabetic mice. BVT-116429 can increase plasma adiponectin levels in diabetic KKAy mice, reduce basal insulin levels, and reduce fasting blood glucose levels after 10 days of inhibition, similar to the effect of rosiglitazone.

HY-P3621

Biotinyl-Glucagon (1-29), human, bovine, porcine	GCGR	Metabolic Disease
Biotinyl-Glucagon (1-29), human, bovine, porcine is a biotinylated glucagon. Glucagon is a peptide hormone, produced by α-cells of the pancreas, can increase concentration of glucose and fatty acids in the bloodstream .

HY-155034

Antitumor agent-102	Topoisomerase GLUT	Cancer
Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .

HY-P2979A

Invertase, candida sp. β-D-Fructofuranosidase, candida sp.	Biochemical Assay Reagents	Others
Invertase from Candida sp. is responsible for catalyzing the hydrolysis of sucrose into glucose and fructose and is widely used in the field of carbohydrate processing. Invertase from Candida sp. can be used for enzymatic determination of sucrose concentration as well as for structural analysis of carbohydrates containing β-D-fructofuranosyl residues .

HY-125327

YM-543	Others	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

HY-139792

Besigliptin tosylate SHR117887	Others	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

HY-19824

3PO Maximum Cited Publications 21 Publications Verification	Autophagy	Cancer
3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC₅₀s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD ⁺ and NADH. 3PO can be used for the research of cancer .

HY-108615

CP-316819 GPi 819	Others	Endocrinology
CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC₅₀ values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively).CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-113513

5-HEPE	Others	Cancer
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

HY-B1876

Nicosulfuron	Acetolactate Synthase (ALS) Photosystem II Fungal	Others
Nicosulfuron is efficient, harmless, antifungal and selective herbicide belonging to the sulfonylurea family. Nicosulfuron is also a photosynthetic system inhibitor and inhibits acetolactate synthase (ALS) enzyme activity. Nicosulfuron degradation by Plectosphaerella cucumerina AR1 is glucose concentration dependent in planktonic lifestyle. Nicosulfuron enhances the glycolysis pathway and tricarboxylic acid cycle to improve the adaptability of sweet maize. Nicosulfuron reduces the synthesis of branched-chain amino acids (BCAAs), which is proming for maize cultivation .

HY-151486

GLUT1-IN-1	GLUT	Cancer
GLUT1-IN-1 is a glucose transporter 1 (GLUT1) inhibitor and has a GLUT1-specific inactivation ability. GLUT1-IN-1 exhibits concentration-dependent cytotoxicity for HeLa, A549 and HepG2 cells with IC₅₀ values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. GLUT1-IN-1 can be used for the research of photodynamic therapy (PDT) and severals cancer .

HY-W250795B

Maltodextrin, dextrose equivalent 5.0-8.0	Endogenous Metabolite	Others
Maltodextrin, dextrose equivalent 5.0-8.0 can be used as an excipient. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs. Dextrose Equivalent (DE) expresses the number of reducing ends aldehyde groups relative to pure glucose at the same concentration, so that high DE indicates high hydrolytic conversion and lower average molecular mass .

HY-124399

N-Octadecyl-N'-propyl-sulfamide	Endogenous Metabolite PPAR	Metabolic Disease
Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating lipid and glucose metabolism, and oleoylethanolamide (OEA) is a natural ligand for PPARα. N-Octadecyl-N'-propyl-sulfamide is an analog of OEA and a potent activator of PPARα, with selective binding affinity for PPARα (EC50=100 nM, compared to 120 nM for OEA). N-Octadecyl-N'-propyl-sulfamide (10 mg/kg; ip) inhibits food intake and reduces body weight gain in rats. At a dose of 1 mg/kg, N-Octadecyl-N'-propyl-sulfamide induces satiety, thereby reducing food intake, body weight, and plasma triglyceride concentrations in free-feeding Wistar rats and obese Zucker (fa/fa) rats.

Cat. No.	Product Name

HY-L045

Oxygen Sensing Compound Library	2,742 compounds
Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival. HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation. MCE offers a unique collection of 2,742 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Oxygen Sensing Compound Library

2,742 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 2,742 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Type

HY-158583

13-POHSA	Native Proteins
13-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

HY-W250795B

Maltodextrin, dextrose equivalent 5.0-8.0	Carbohydrates
Maltodextrin, dextrose equivalent 5.0-8.0 can be used as an excipient. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs. Dextrose Equivalent (DE) expresses the number of reducing ends aldehyde groups relative to pure glucose at the same concentration, so that high DE indicates high hydrolytic conversion and lower average molecular mass .

Maltodextrin, dextrose equivalent 5.0-8.0

Carbohydrates

Maltodextrin, dextrose equivalent 5.0-8.0 can be used as an excipient. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs. Dextrose Equivalent (DE) expresses the number of reducing ends aldehyde groups relative to pure glucose at the same concentration, so that high DE indicates high hydrolytic conversion and lower average molecular mass .

Cat. No.	Product Name	Target	Research Area

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P3621

Biotinyl-Glucagon (1-29), human, bovine, porcine	GCGR	Metabolic Disease
Biotinyl-Glucagon (1-29), human, bovine, porcine is a biotinylated glucagon. Glucagon is a peptide hormone, produced by α-cells of the pancreas, can increase concentration of glucose and fatty acids in the bloodstream .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-109500

Masoprocol meso-Nordihydroguaiaretic acid; meso-NDGA	other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Cancer	Lipoxygenase
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

HY-113513

5-HEPE	Microorganisms Source classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

glucose concentration

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products